Shui He
Impact in
- Genetics top 1%
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Hematology top 2%
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
Papers in
- Co-authors
- Kyle J. Gunnerson (1 shared paper)Melissa Saul (1 shared paper)John A. Kellum (1 shared paper)Alessandro M. Vannucchi (11 shared papers)Srđan Verstovšek (11 shared papers)Francesco Passamonti (7 shared papers)Jingjin Li (8 shared papers)Jean‐Jacques Kiladjian (8 shared papers)
- Journals
- Blood (15 papers)Journal of Clinical Oncology (3 papers)Hematological Oncology (2 papers)Environmetrics (2 papers)Critical Care (2 papers)
- Partner nations
- United StatesItalyUnited Kingdom
In The Last Decade
Shui He
38 papers receiving 1.7k citations
Shui He's Hit Papers
Peers
Comparison fields: 5 of 104
- Genetics 752
- Hematology 434
- Nephrology 159
- Rheumatology 297
- Oncology 523
Countries citing papers authored by Shui He
This map shows the geographic impact of Shui He's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shui He with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shui He more than expected).
Fields of papers citing papers by Shui He
This network shows the impact of papers produced by Shui He. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shui He. The network helps show where Shui He may publish in the future.
Co-authors
The 25 scholars most cited alongside Shui He, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 38 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera Hit paper breakdown → | 2015 | 637 |
| 2 | Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial Hit paper breakdown → | 2021 | 284 |
| 3 | 2006 | 278 | |
| 4 | 2013 | 135 | |
| 5 | 2019 | 82 | |
| 6 | 2021 | 68 | |
| 7 | 2005 | 43 | |
| 8 | 2018 | 37 | |
| 9 | 2006 | 18 | |
| 10 | 2018 | 17 | |
| 11 | 2014 | 14 | |
| 12 | 2020 | 13 | |
| 13 | 2012 | 13 | |
| 14 | 2014 | 12 | |
| 15 | 2018 | 11 | |
| 16 | 2017 | 9 | |
| 17 | 2018 | 9 | |
| 18 | 2021 | 8 | |
| 19 | 2017 | 8 | |
| 20 | 2019 | 8 |
About Shui He
Shui He is a scholar working on Genetics, Oncology, Hematology, Organic Chemistry and Molecular Biology, having authored 38 papers that have together received 1.8k indexed citations. Recurring topics across this work include Myeloproliferative Neoplasms: Diagnosis and Treatment (11 papers), CAR-T cell therapy research (6 papers), Acute Myeloid Leukemia Research (6 papers), Synthesis and pharmacology of benzodiazepine derivatives (6 papers), Lymphoma Diagnosis and Treatment (6 papers), HER2/EGFR in Cancer Research (5 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Hemoglobinopathies and Related Disorders (4 papers). The work is most often cited by research in Genetics (752 citations), Hematology (434 citations), Nephrology (159 citations), Rheumatology (297 citations) and Oncology (523 citations). Shui He has collaborated with scholars based in United States, Italy and United Kingdom. Frequent co-authors include Kyle J. Gunnerson, Melissa Saul, John A. Kellum, Alessandro M. Vannucchi, Srđan Verstovšek, Francesco Passamonti, Jingjin Li, Jean‐Jacques Kiladjian, Ruben A. Mesa and Pierre Zachée. Their work appears in journals such as Blood, Journal of Clinical Oncology, Hematological Oncology, Environmetrics and Critical Care.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.